FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034992783> ?p ?o ?g. }

• W2034992783 endingPage "582" @default.
• W2034992783 startingPage "577" @default.
• W2034992783 abstract "Introduction: The aim of this phase II study was to evaluate response and toxicity of a prolonged chemoradiation regimen in patients with locally advanced cervical cancer. Patients and Methods: Three cycles of concomitant chemotherapy were used with cisplatin (20 mg/m2, 2-hour intravenous infusion, days 1–4) and 5-fluorouracil (1000 mg/m2, 24-hour continuous intravenous infusion, days 1–4) administered at weeks 1, 5, and 9 of radiotherapy. In combination, radiotherapy was delivered to a planning target volume (PTV) defined as the CTV (clinical target volume) plus 8 mm. The CTV was defined as follows: gross tumor volume, upper half of the vagina (if not involved) or the whole vagina (if clinically involved), uterus, obturator nodes, external iliac nodes, internal iliac nodes, and the presacral nodes (cranial to S2). The prescribed dose to the PTV was 50 Gy, 2 Gy/fraction (ICRU 62) delivered in 25 fractions with a 2-week break at 20Gy and 40 Gy (split-course technique). Early and late toxicity was assessed according to the RTOG and RTOG/EORTC toxicity scales. Perioperative toxicity was evaluated according to the Chassagne classification of surgical complications. Results: A total of 25 patients were included in this study. Median age was 52 years (range, 28–69). Clinical stage was: IB2-II: 19 patients (76%), III–IVA: 6 patients (24%). All patients completed the prescribed dose of chemoradiation and were evaluated 4 weeks after the end of treatment. Complete and partial clinical local response was observed in 4 and 19 patients, respectively (totaling 92% of clinical responses). About 32% of patients experienced grade 3 to 4 toxicity, in particular, grade 3 or 4 hematological toxicity was observed in 7 patients and 1 patient developed grade 3 genitourinary toxicity. No patients developed grade 3 gastrointestinal toxicity or skin toxicity. Of total, 22 patients (88%) underwent radical hysterectomy. Seven patients (28%) showed a complete response (CR) to treatment, and 7 patients (28%) showed microscopic residual disease (μPR), totaling 14 patients (56%) complete/partial microscopic responses. Perioperative morbidity was higher than reported in historical controls especially in terms of tissue fibrosis (64%) and perioperative urinary toxicity (14%). Actuarial 2-year local control, disease-free survival, and overall survival were 65.5%, 61.8%, and 80.8%, respectively. Conclusion: A prolonged treatment with more chemotherapy courses does not improve tumor response and increases the risk of perioperative complication. This treatment regimen, considering the low incidence of acute gastrointestinal toxicity, might be tested in the adjuvant setting." @default.
• W2034992783 created "2016-06-24" @default.
• W2034992783 creator A5005084881 @default.
• W2034992783 creator A5008208200 @default.
• W2034992783 creator A5030229940 @default.
• W2034992783 creator A5030733912 @default.
• W2034992783 creator A5038579623 @default.
• W2034992783 creator A5051494397 @default.
• W2034992783 creator A5061939825 @default.
• W2034992783 creator A5070096760 @default.
• W2034992783 creator A5077596666 @default.
• W2034992783 creator A5089721939 @default.
• W2034992783 date "2010-12-01" @default.
• W2034992783 modified "2023-10-10" @default.
• W2034992783 title "Prolonged Chemoradiation in Locally Advanced Carcinoma of the Uterine Cervix" @default.
• W2034992783 cites W1935824237 @default.
• W2034992783 cites W1966798451 @default.
• W2034992783 cites W1970452171 @default.
• W2034992783 cites W1971465280 @default.
• W2034992783 cites W1974720222 @default.
• W2034992783 cites W1975293611 @default.
• W2034992783 cites W1980179957 @default.
• W2034992783 cites W1987084635 @default.
• W2034992783 cites W1990828990 @default.
• W2034992783 cites W1998538870 @default.
• W2034992783 cites W2013601452 @default.
• W2034992783 cites W2022356343 @default.
• W2034992783 cites W2022636355 @default.
• W2034992783 cites W2029409133 @default.
• W2034992783 cites W2043945205 @default.
• W2034992783 cites W2056559030 @default.
• W2034992783 cites W2075543032 @default.
• W2034992783 cites W2077232055 @default.
• W2034992783 cites W2138808833 @default.
• W2034992783 cites W2139248078 @default.
• W2034992783 cites W2152292894 @default.
• W2034992783 cites W2169682472 @default.
• W2034992783 cites W2314753133 @default.
• W2034992783 cites W2324392028 @default.
• W2034992783 cites W2328935341 @default.
• W2034992783 cites W4293241248 @default.
• W2034992783 doi "https://doi.org/10.1097/coc.0b013e3181b9cf5c" @default.
• W2034992783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20023568" @default.
• W2034992783 hasPublicationYear "2010" @default.
• W2034992783 type Work @default.
• W2034992783 sameAs 2034992783 @default.
• W2034992783 citedByCount "12" @default.
• W2034992783 countsByYear W20349927832012 @default.
• W2034992783 countsByYear W20349927832013 @default.
• W2034992783 countsByYear W20349927832014 @default.
• W2034992783 countsByYear W20349927832015 @default.
• W2034992783 countsByYear W20349927832017 @default.
• W2034992783 countsByYear W20349927832022 @default.
• W2034992783 countsByYear W20349927832023 @default.
• W2034992783 crossrefType "journal-article" @default.
• W2034992783 hasAuthorship W2034992783A5005084881 @default.
• W2034992783 hasAuthorship W2034992783A5008208200 @default.
• W2034992783 hasAuthorship W2034992783A5030229940 @default.
• W2034992783 hasAuthorship W2034992783A5030733912 @default.
• W2034992783 hasAuthorship W2034992783A5038579623 @default.
• W2034992783 hasAuthorship W2034992783A5051494397 @default.
• W2034992783 hasAuthorship W2034992783A5061939825 @default.
• W2034992783 hasAuthorship W2034992783A5070096760 @default.
• W2034992783 hasAuthorship W2034992783A5077596666 @default.
• W2034992783 hasAuthorship W2034992783A5089721939 @default.
• W2034992783 hasConcept C121608353 @default.
• W2034992783 hasConcept C126322002 @default.
• W2034992783 hasConcept C126894567 @default.
• W2034992783 hasConcept C141071460 @default.
• W2034992783 hasConcept C146357865 @default.
• W2034992783 hasConcept C151730666 @default.
• W2034992783 hasConcept C2776694085 @default.
• W2034992783 hasConcept C2777740455 @default.
• W2034992783 hasConcept C2778220009 @default.
• W2034992783 hasConcept C2779384505 @default.
• W2034992783 hasConcept C2781413609 @default.
• W2034992783 hasConcept C29730261 @default.
• W2034992783 hasConcept C2989005 @default.
• W2034992783 hasConcept C31174226 @default.
• W2034992783 hasConcept C31760486 @default.
• W2034992783 hasConcept C509974204 @default.
• W2034992783 hasConcept C71924100 @default.
• W2034992783 hasConcept C86803240 @default.
• W2034992783 hasConceptScore W2034992783C121608353 @default.
• W2034992783 hasConceptScore W2034992783C126322002 @default.
• W2034992783 hasConceptScore W2034992783C126894567 @default.
• W2034992783 hasConceptScore W2034992783C141071460 @default.
• W2034992783 hasConceptScore W2034992783C146357865 @default.
• W2034992783 hasConceptScore W2034992783C151730666 @default.
• W2034992783 hasConceptScore W2034992783C2776694085 @default.
• W2034992783 hasConceptScore W2034992783C2777740455 @default.
• W2034992783 hasConceptScore W2034992783C2778220009 @default.
• W2034992783 hasConceptScore W2034992783C2779384505 @default.
• W2034992783 hasConceptScore W2034992783C2781413609 @default.
• W2034992783 hasConceptScore W2034992783C29730261 @default.
• W2034992783 hasConceptScore W2034992783C2989005 @default.
• W2034992783 hasConceptScore W2034992783C31174226 @default.
• W2034992783 hasConceptScore W2034992783C31760486 @default.

• next